← Evidence map

ArticleCancers2025

Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience.

Carolin M Reiner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience. | OpenQuestion